COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth
The chronic obstructive pulmonary disease (COPD) market continues its trajectory of rapid growth, bolstered by significant advancements in biologics and sustained investments by major pharmaceutical players. AstraZeneca’s recent presentation at the JPM …